Pluri (NASDAQ:PLUR) Issues Earnings Results

Pluri (NASDAQ:PLUR) issued its quarterly earnings data on Thursday. The company reported ($0.71) earnings per share for the quarter, Zacks reports. The company had revenue of $0.20 million during the quarter.

Pluri Stock Up 3.0%

NASDAQ:PLUR opened at $3.66 on Friday. The stock’s fifty day moving average is $3.25 and its two-hundred day moving average is $4.01. Pluri has a 52 week low of $2.82 and a 52 week high of $7.13. The stock has a market capitalization of $36.48 million, a price-to-earnings ratio of -0.74 and a beta of 0.67.

Institutional Investors Weigh In On Pluri

A hedge fund recently bought a new stake in Pluri stock. Jane Street Group LLC bought a new position in shares of Pluri Inc. (NASDAQ:PLUR) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 10,928 shares of the company’s stock, valued at approximately $47,000. Jane Street Group LLC owned approximately 0.14% of Pluri at the end of the most recent quarter. Institutional investors and hedge funds own 16.59% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pluri in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Pluri currently has an average rating of “Hold” and an average target price of $12.00.

About Pluri

Pluri (NASDAQ:PLUR) is a clinical-stage biotechnology company focused on the development and manufacturing of placental-derived cell therapy products. The company’s proprietary three-dimensional microcarrier expansion platform enables large-scale, off-the-shelf production of PLX (placental expanded) cells, which are being investigated for a range of acute and chronic conditions. Pluri’s approach seeks to combine the regenerative and immunomodulatory properties of stromal cells with a scalable manufacturing process that does not require patient-specific cell harvesting.

Pluri advances its pipeline through internally funded research programs and strategic collaborations with academic institutions and government agencies.